Donald H. Batts and G. Ralph Corey have been named to Trius Therapeutics' (San Diego) clinical advisory board. Batts is a professor of medicine at Michigan State University and the chief of infectious diseases at its Kalamazoo campus. Corey is the Gary Hock Distinguished Professor of Global Health and the director of the Hubert/Yeargan Center for Global Health and director of infectious disease research at the Duke Clinical Research Institute.

George Bobotas has joined Halo Pharmaceutical (Whippany, NJ, USA) as chief scientific officer as part of an R&D partnership between Halo Pharmaceutical and DeMelleBioPharma. Bobotas has been president and managing partner of DeMelleBioPharma since 2008. He previously served as vice president, scientific affairs at Reliant Pharmaceuticals, a subsidiary of GlaxoSmithKline.

Microbia (Lexington, MA, USA) has appointed Mike Doyle to the newly created position of senior vice president and general manager of nutrition ingredients. He brings more than 12 years of executive management experience, previously at BASF and most recently as president of LycoRed in North America.

A. Paul Cox, Jr., chairman of the board of Spherix (Bethesda, MD, USA), passed away on April 13, 2009, at the age of 71. Cox had been a board member since 2004 and was elected chairman in 2007. Spherix's board has elected Robert J. Vander Zanden to serve as interim chairman until the 2009 annual shareholders meeting, following which the board will elect a new slate of officers to serve for the 2009–2010 term.

Alnara Pharmaceuticals (Cambridge, MA, USA) has promoted Robert Gallotto to chief business officer. Gallotto was most recently senior vice president, operations and corporate development for the company.

Codexis (Redwood City, CA, USA) has named Lori Giver (right) to the newly created position of vice president, systems biology for Codexis Bioindustrials. She joined Codexis from Maxygen in 2002 and most recently served as senior director, evolution technology.

Jesse Goodman, formerly director of the US Food & Drug Administration's Center for Biologics Evaluation and Research, has been promoted to the position of FDA's chief medical officer. In addition, he will serve as the agency's representative on the recently created Federal Coordinating Committee on Comparative Effectiveness.

Privately held Tigris Pharmaceuticals (Bonita Springs, FL, USA) has named Pedro Granadillo chairman of its board of directors. Granadillo has over 30 years of experience in corporate management. He retired in 2004 after 34 years at Eli Lilly, holding positions including senior vice president, member of Lilly's executive committee and head of human resources, manufacturing and quality. Granadillo currently serves on the boards of directors of Haemonetics, Noven Pharmaceuticals and Nile Therapeutics.

LifeCycle Pharma (Hørsholm, Denmark) announced today that executive vice president and chief medical officer Karin Hamberg has stepped down from her position to pursue other career opportunities. She joined the company in June 2008 and became chief medical officer in November 2008.

Richard Hollis, founding CEO of Hollis-Eden Pharmaceuticals (San Diego), has stepped down as chairman and CEO of the company. He will continue serving as a member of the board. Chief scientific officer James M. Frincke has been named interim CEO and Salvatore Zizza has been named the nonexecutive chairman. Zizza has served as a member of Hollis-Eden's board since March 1997.

Repros Therapeutics (The Woodlands, TX, USA) has named Stephen B. Howell to its board of directors. Howell is professor of medicine at the University of California, San Diego and currently serves as associate director for clinical research and director of the cancer therapeutics training program at the Moores Comprehensive Cancer Center.

Hatchtech (Melbourne, Australia) has announced the resignation of Paul MacLeman as CEO and director. MacLeman will take up the CEO role at a high-profile, publicly listed biotech company. He joined Hatchtech in 2005.

Yissum Research Development Company (Jerusalem), the technology transfer arm of the Hebrew University of Jerusalem, has named Yaacov Michlin CEO and announced that Yehuda Yarmut, who until recently was executive vice president, licensing & intellectual property, was promoted and appointed deputy CEO. Over the past 12 years, Michlin has led and assisted pharma, high-tech and biomedical companies in various technology commercialization deals, licensing agreements, capital raising activities, partnerships, mergers and acquisitions.

Auspex Pharmaceuticals (Vista, CA, USA) has announced three key management hires. Ronald C. Newbold has been named chief business officer; Andreas Sommer has been appointed vice president, operations; and Tadimeti Rao has been named vice president, preclinical development. Newbold joins Auspex from Celldex Therapeutics where he was senior vice president of business development. Sommer has 20 years of experience as a senior executive at public and private biotech companies, most recently serving as chief scientific officer at Insmed. And Rao joins Auspex from Kalpsys, where he was director of pharmacology and preclinical development.

Yongye Biotechnology International (Beijing) has announced the appointment of Sam Yu as chief financial officer. He replaces Larry Gilmore, who becomes vice president of corporate strategy and remains the company's primary investor relations contact. Before joining Yongye, Yu provided consulting services to assist Chinese companies in listing on the Nasdaq Stock Market and previously served as COO of Lionax International Investment Holding.

Mark Wiggins has joined Mpex Pharmaceuticals (San Diego) as chief business officer. He joins the company from Biogen Idec, where he most recently served as executive vice president of business development, and was a member of the executive committee.